Explore

Rapid Read Rapid Read
Proteomics Study Suggests ALS Could Be Predicted Years Before Symptoms

Proteomics Study Suggests ALS Could Be Predicted Years Before Symptoms

A study published in Nature Medicine has identified blood protein markers that could predict the onset of amyotrophic lateral sclerosis (ALS) years before symptoms appear. Researchers analyzed data from the Pre-symptomatic Familial ALS (Pre-fALS) study, identifying key proteins that change in levels before clinical symptoms manifest. The study used machine-learning techniques to predict the timing of symptom onset with an average error of 18 months. This research offers a potential pathway for early intervention in ALS, allowing for preventative therapies before irreversible motor neuron damage occurs.
Rapid Read Rapid Read
ProMIS Neurosciences to Present Interim Data on Alzheimer's Treatment

ProMIS Neurosciences to Present Interim Data on Alzheimer's Treatment

ProMIS Neurosciences is set to host a webinar to discuss the six-month blinded interim data from its PRECISE-AD Phase 1b trial of PMN310, a treatment for Alzheimer's disease. The trial focuses on evaluating the safety, tolerability, and pharmacokinetics of PMN310 in patients with early Alzheimer's. The analysis will include aggregate safety data and trends in select biomarkers. PMN310 is designed to target toxic oligomers of amyloid-beta, which are believed to be early drivers of Alzheimer's, while avoiding amyloid plaques. The trial has enrolled 144 participants and aims to provide insights into the effects of PMN310 on biomarkers and clinical outcomes.
Rapid Read Rapid Read
Researchers Explore Immunotherapy Targeting Microglia for Alzheimer's Treatment

Researchers Explore Immunotherapy Targeting Microglia for Alzheimer's Treatment

Researchers are investigating the potential of immunotherapy targeting the brain's immune cells, specifically microglia, as a treatment for Alzheimer's disease. The focus is on the TREM2 receptor, which is crucial for the protective abilities of microglia against beta-amyloid plaques, a hallmark of Alzheimer's. A drug called AL002, developed by Alector, was designed to activate the TREM2 receptor. However, in a Phase 2 trial, AL002 failed to slow cognitive decline and caused high rates of brain swelling and microhemorrhages. Despite this setback, experts believe that targeting TREM2 remains a promising strategy for Alzheimer's treatment.
Rapid Read Rapid Read
Scientists Identify Brain Immune Cells as Key to Alzheimer's Resilience

Scientists Identify Brain Immune Cells as Key to Alzheimer's Resilience

A recent study published in Nature Medicine has provided new insights into why some individuals develop dementia while others do not, despite having Alzheimer's-related brain changes. Researchers analyzed brain tissue from older adults with and without cognitive decline, as well as cognitively healthy centenarians. The study focused on microglia, the brain's immune cells, which appear to play a crucial role in determining whether Alzheimer's disease progresses to dementia. The findings suggest that the way these immune cells respond to Alzheimer's-related damage could be pivotal. The research indicates that maintaining a healthy immune response within the brain might be as important as removing amyloid plaques, which have been a primary focus in Alzheimer's research.
Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Trendline Trendline
Clinical Research Associates Play Key Role in Patient Safety and Data Integrity

Clinical Research Associates Play Key Role in Patient Safety and Data Integrity

Clinical Research Associates Play Key Role in Patient Safety and Data Integrity
Rapid Read Rapid Read
Kenai Completes Enrollment for Parkinson’s Cell Therapy Trial

Kenai Completes Enrollment for Parkinson’s Cell Therapy Trial

Kenai Therapeutics has completed enrollment for its Phase 1b/2a REPLACE clinical trial, which investigates RNDP-001, a cell therapy aimed at replacing lost brain cells in Parkinson’s disease patients. This trial marks a shift from traditional treatments that manage symptoms to potentially regenerative approaches. The therapy uses an off-the-shelf model, allowing for pre-manufactured treatments that could be more accessible and scalable. The trial will assess the safety and efficacy of RNDP-001, with initial results expected after patient follow-up. This development could significantly impact the treatment landscape for neurodegenerative diseases.
Rapid Read Rapid Read
Researchers Identify Brain Receptor Mechanism for Weight Loss Drugs

Researchers Identify Brain Receptor Mechanism for Weight Loss Drugs

Researchers at the Institute of Metabolic Science, University of Cambridge, have discovered how both stimulating and blocking a brain receptor, GIPR, can aid in weight loss. The study, conducted on mice, revealed that stimulating GIPR in the brainstem suppresses appetite, while blocking it in the hypothalamus achieves a similar effect. This research could lead to the development of more effective obesity treatments. The study highlights the role of dual agonists for the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) in managing type 2 diabetes and obesity. The findings suggest that GIPR agonists and antagonists act on different brain regions, enhancing weight loss when combined with GLP-1-based drugs.
Rapid Read Rapid Read
AbbVie Focuses on Biomarkers to Advance Parkinson's Disease Research

AbbVie Focuses on Biomarkers to Advance Parkinson's Disease Research

AbbVie is shifting its research focus from symptom management to disease modification in Parkinson's disease. Dr. Jan Stoehr, a neuroscience researcher at AbbVie, highlighted the importance of targeting the underlying disease biology to potentially slow disease progression. The company is utilizing biomarkers to identify biological changes earlier, which can help in understanding disease progression and determining patient eligibility for clinical trials. This approach aims to intervene before the disease spreads across the brain, addressing both symptoms and the underlying disease biology. The use of multimodal biomarkers is emphasized to improve early detection, patient stratification, and measure disease progression.
Rapid Read Rapid Read
APOE2 Gene Offers New Insights into Brain Aging and Longevity

APOE2 Gene Offers New Insights into Brain Aging and Longevity

Recent research from the Buck Institute for Research on Aging has uncovered the protective effects of the APOE2 gene variant on brain DNA, potentially reshaping approaches to brain health and longevity. The study reveals that APOE2, a variant of the apolipoprotein E gene, is linked to longer lifespan and reduced risk of Alzheimer's disease. Unlike the APOE4 variant, which increases Alzheimer's risk, APOE2 enhances DNA repair and reduces cellular senescence in neurons, offering a robust defense against neurodegeneration.
Rapid Read Rapid Read
New Alzheimer's Research Identifies Key Biological Shift in Disease Progression

New Alzheimer's Research Identifies Key Biological Shift in Disease Progression

Researchers have identified a major biological shift that may determine whether Alzheimer's disease leads to dementia. The study, based on human donor material, highlights changes in microglia, the brain's immune cells, as a potential focus for future treatments. The findings suggest that resilience to Alzheimer's damage may depend on how the brain adapts its response to pathology. This research opens new avenues for therapies aimed at preventing neurodegeneration and cognitive decline.
Rapid Read Rapid Read
Microglia Identified as Key Drivers of Sleep Loss in Alzheimer's Disease

Microglia Identified as Key Drivers of Sleep Loss in Alzheimer's Disease

Researchers at the University of Kentucky have discovered that microglia, the brain's immune cells, are the main drivers of sleep loss in mice with Alzheimer's-like disease. The study, published in Alzheimer's & Dementia, found that temporarily eliminating most microglia with a drug restored over two hours of sleep each day in the animal models. This finding challenges previous assumptions that sleep disruption in Alzheimer's was primarily due to dying neurons or amyloid plaques. Instead, the research points to a broader inflammatory response involving the brain's immune system, offering a potential new target for treatment.